🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Harmony Biosciences will be announcing the Company’s Q4 and Full Year 2024 financial results on February 25 during an earnings call. Learn more: bit.ly/3QnGfC7 #InvestorRelations #IR #Biosciences #lifesciences

We are proud to sponsor an important discussion with Washington Post Live in honor of #RareDiseaseDay, marking the second year of our program dedicated to advancing the national conversation around rare diseases and emphasizing the critical role of social support systems and caregiving.

Earlier today, Harmony Biosciences announced the Company’s Q4 and Full Year 2024 financial results. Read our news release for more information: bit.ly/3DfBkA8 #Biosciences #LifeSciences #RareDisease #RareDiseases

This month, Harmony Biosciences’ Management Team will be participating in two global healthcare conferences in Miami. Learn more about our evolving pipeline and commitment to developing new treatment options for people living with rare neurological diseases who have unmet medical

Earlier today, we announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer of Harmony Biosciences, effective March 31, 2025. We are excited to welcome Adam to the organization as he leads Harmony’s next phase of commercial growth and

On April 9, Harmony Biosciences’ Management Team will be participating in the 24th Annual Needham Virtual Healthcare conference. Learn more about our evolving pipeline and commitment to developing new treatment options for people living with rare #neurological diseases who have

We are pleased to announce the appointment of Ron Philip to Harmony Biosciences’ Board of Directors. He currently serves as President and Chief Executive Officer of Orbital Therapeutics and has 30 years of experience building companies, leading organizational growth, and guiding

Excited to be at this year’s Dravet Syndrome Foundation European Conference! This gathering of experts, researchers, and advocates gives us the opportunity to advance conversations around #DravetSyndrome and #epilepsy care. Learn more about our commitment: Harmony Biosciences Focus Area:

We are pleased to announce that our open-label extension data from our Fragile X syndrome clinical development program will be presented at the American Academy of Neurology Annual Meeting as a podium presentation today. For more information, visit: bit.ly/43KXWng

#AutismAcceptanceMonth: Through innovative science and a deep commitment to patients, we strive to help address unmet medical needs in the #FragileX syndrome community. Learn more about our research: bit.ly/426e1m5 #FragileXAwareness #FXS #RareDisease #RareDiseases

Harmony Biosciences will be announcing the Company’s Q1 2025 financial results on May 6, 2025 during an earnings call. Learn more: bit.ly/3GK6L71 #InvestorRelations #IR #Biosciences #LifeSciences

#PWSAwarenessMonth: Despite the impact of #PraderWillisyndrome symptoms on daily life, there is a need for additional FDA-approved treatments. Raising awareness and advancing research are crucial steps toward improving care and support. Join us in raising awareness and advocating

Earlier today, Harmony Biosciences announced the Company’s Q1 2025 financial results, which included an announcement of the completion of enrollment in our RECONNECT Phase 3 trial evaluating the safety and efficacy of a potential treatment option in people with Fragile X syndrome

Enrollment is now complete for our Phase 3 RECONNECT study in #FragileXsyndrome, a major step toward the potential first-ever FDA-approved treatment for #FXS. At Harmony Biosciences, empathy and innovation fuel our work. Hear from Jim Cantore (Jim Cantore), a meteorologist and

In honor of #NursesWeek, Michele Roy, RN, MS, who leads our Regulatory Affairs team, reflects back on her career as a critical care nurse. The patients she cared for continue to shape how she approaches her work today: with empathy, focus, and a deep commitment to active

DYK: #FragileXsyndrome (FXS) affects both genders, but boys often experience more severe symptoms? At Harmony Biosciences, we’re advancing potential breakthroughs that could help move patient care forward for those living with #FXS and other neurological conditions:

Harmony Biosciences is excited to be attending the American Psychiatric Association Annual Meeting in Los Angeles this year. We’re looking forward to connecting with thought leaders, researchers, and innovators to explore the latest advancements in neuroscience. If you’re attending, we’re at

We’re excited to be part of the 39th Annual Meeting of the Associated Professional Sleep Societies! It's a privilege to connect with healthcare professionals and advocates to help advance the science and clinical practice of sleep medicine. #SleepMedicine #SleepResearch

On June 9, Harmony Biosciences’ Management Team will be participating in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. Learn more about our evolving pipeline and commitment to developing new treatment options for people living with rare

Earlier today, we shared a business update reinforcing the validity and strength of Harmony Biosciences’ intellectual property portfolio, which continues to protect our #innovation in sleep/wake therapeutics. Read more: bit.ly/3FIaQbN #Biosciences #LifeSciences